Abstract:Rare diseases are usually chronically debilitating or even life-threatening with diagnostic and therapeutic challenges in current clinical practice. It has been estimated that 80% of rare diseases are genetic in origin, and thus genome sequencing-based diagnosis offers a promising alternative for rare-disease management. In this study, 79 individuals from 16 independent families were performed for whole-genome sequencing (WGS) in an effort to identify the causative mutations for 16 distinct rare diseases that are largely clinically intractable. Comprehensive analysis of variations, including simple nucleotide variants (SNVs), copy-number variations (CNVs), and structural variations (SVs), was implemented using the WGS data. A flexible analysis pipeline that allowed a certain degree of misclassification of disease status was developed to facilitate the identification of causative variants. As a result, disease-causing variants were identified in 10 of the 16 investigated diseases, yielding a diagnostic rate of 62.5%. Additionally, new potentially pathogenic variants were discovered for two disorders, including IGF2/INS-IGF2 in mitochondrial disease and FBN3 in Klippel–Trenaunay–Weber syndrome. Our WGS analysis not only detected a CNV associated with 3p deletion syndrome but also captured a simple sequence repeat (SSR) variation associated with Machado–Joseph disease. To our knowledge, this is the first time the clinical WGS analysis of short-read sequences has been used successfully to identify a causative SSR variation that perfectly segregates with a repeat expansion disorder. After the WGS analysis, we confirmed the initial diagnosis for three of 10 established disorders and modified or corrected the initial diagnosis for the remaining seven disorders. In summary, clinical WGS is a powerful tool for the diagnosis of rare diseases, and its diagnostic clarity at molecular levels offers important benefits for the participating families.

Using Off-Target Data from Whole-Exome Sequencing to Improve Genotyping Accuracy, Association Analysis and Polygenic Risk Prediction.

Efficient Identification of Trait-Associated Loss-of-function Variants in the UK Biobank Cohort by Exome-Sequencing Based Genotype Imputation

Implementation of whole-exome sequencing for pharmacogenomics profiling and exploring its potential clinical utilities

Diagnostic and Clinical Utility of Whole Genome Sequencing in a Cohort of Undiagnosed Chinese Families with Rare Diseases

Application of whole exome sequencing in carrier screening for high-risk families without probands

Development of a coding SNP panel for tracking the origin of whole-exome sequencing samples

A cost-effective sequencing method for genetic studies combining high-depth whole exome and low-depth whole genome

Enhancing Clinical Applications by Evaluation of Sensitivity and Specificity in Whole Exome Sequencing

Enhancing Variant Calling in Whole-Exome Sequencing Data Using Population-Matched Reference Genomes.

Enhancing Variant Calling in Whole Exome Sequencing (WES) Data Using Population-Matched Reference Genomes

Exome sequencing and analysis of 454,787 UK Biobank participants

Advancing Personalized Medicine Through the Application of Whole Exome Sequencing and Big Data Analytics

ERDS-Exome: A Hybrid Approach for Copy Number Variant Detection from Whole-Exome Sequencing Data

Clinical application of whole-exome sequencing across clinical indications

Identifying novel genetic and phenotypic associations to genomic features by leveraging off-target reads in exome sequencing data

Openness weighted association studies: leveraging personal genome information to prioritize non-coding variants

Global Inference of Disease-Causing Single Nucleotide Variants from Exome Sequencing Data

Yield of genetic association signals from genomes, exomes and imputation in the UK Biobank

Targeted Gene Panel Provides Advantages over Whole-Exome Sequencing for Diagnosing Obesity and Diabetes Mellitus.

An evaluation of copy number variation detection tools from whole-exome sequencing data.

Systematic dissection of biases in whole-exome and whole-genome sequencing reveals major determinants of coding sequence coverage